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Abstract
Öz
Amaç: Embriyo transferi öncesi uterin kaviteye gonadotropin serbestleştirici hormon agonisti (GnRHa) enjeksiyonunun implantasyon ve gebelik oranlarına 
etkisini değerlendirmektir.
Gereç ve Yöntemler: Ocak 2012-Mart 2013 tarihleri arasında üniversite hastanemizin in vitro fertilizasyon (IVF) kliniğinde IVF tedavilerinden sonra ve 
embriyo transferi öncesinde uterin kaviteye GnRHa enjeksiyonu uygulanan ve uygulanmayan hasta grupları retrospektif olarak tarandı. Her iki grubun 
implantasyon, gebelik, canlı doğum ve düşük oranları karşılaştırıldı.
Bulgular: Bu tarihler arasında uterin kaviteye embriyo transferi öncesi GnRHa enjekte edilen 108 hasta çalışma grubumuz olarak belirlenirken, bu süreçte 
GnRHa enjekte edilmemiş 1047 hasta kontrol grubu olarak kabul edildi. İmplantasyon oranlarına baktığımızda sırasıyla GnRHa ve kontrol grubunda %31 
ve %30, gebelik oranları %44,4 ve %41,7, canlı doğum oranları %27,8 ve %26,1 ve düşük oranları %15,7 ve %15,7 olarak saptanmış ve gruplar arasında 
fark görülmemiştir.
Sonuç: Uterin kaviteye embriyo transferi öncesi GnRHa enjeksiyonunun istatistiksel olarak, implantasyon, gebelik, canlı doğum ve düşük oranlarına bir 
etkisi bulunmamıştır. Bu nedenle, tüp bebek uygulamalarından sonra embriyo transferi öncesi uterin kaviteye GnRHa enjeksiyonu önerilmemektedir. Fakat 
bu konuda prospektif randomize çalışmalara ihtiyaç vardır. 
Anahtar Kelimeler: Gonadotropin serbestleştirici hormon agonisti, embriyo transferi, uterin kavite, in vitro fertilizasyon
Objective: To evaluate the effects of a gonadotropin releasing hormone agonist (GnRHa) injection prior to embryo transfer on implantation and pregnancy 
rate.
Materials and Methods: We performed a retrospective analysis of patients undergoing in vitro fertilization (IVF) therapy with and without GnRHa 
preinstallation into the uterine cavity just before embryo transfer between January 2012 and March 2013 in a single IVF center of a university hospital. 
Patients were evaluated based upon implantation, pregnancy, live birth, and miscarriage rates. 
Results: GnRHa was injected into the uterine cavity of 108 patients prior to embryo transfer which were regarded as study group. One thousand forty-
seven patients who were not injected GnRHa were regarded as the control group. Pregnancy rates were 44.4% and 41.7% in the GnRHa and control groups, 
respectively. Live birth rates were 27.8% and 26.1%, miscarriage rates were 15.7% and 15.7%, and implantation rates were 31% and 30%, respectively and 
there were no difference between groups statistically (p>0.05).
Conclusion: No statistically significant differences in implantation, pregnancy, live birth, or miscarriage rates were observed in patients treated with GnRHa 
prior to embryo transfer, relative to the controls. Therefore, GnRHa injection into the uterine cavity prior to embryo transfer is not recommended as a 
means of increasing implantation or pregnancy rates in IVF. However, prospective randomized controlled studies are needed to clarify the effect of GnRHa 
instillation in the uterine cavity for embryo implantation in IVF.
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Introduction
The success of in vitro fertilization (IVF) as a means of achieving 
clinical pregnancy is primarily dependent on the presence 
of high quality embryos and a suitable endometrium for 
implantation. Although the definition of high quality embryos 
is well established based upon morphologic criteria of the 
cleavage embryo or blastocyst, there remains no widely accepted 
morphologic or structural criterion that is used to assess the 
suitability of the endometrium. Therefore, much of the research 
in IVF has been focused on improving implantation rates 
through processes such as luteal phase support, which is now 
strongly recommended in IVF(1).
Progesterone, estradiol, human chorionic gonadotropin (hCG), 
or gonadotropin releasing hormone agonists (GnRHa) have 
been evaluated in a variety of clinical studies as a means of luteal 
phase support to increase implantation and pregnancy rates in 
IVF(2-5). More recent studies have suggested that intrauterine 
injections of hCG just before embryo transfer (ET) can increase 
pregnancy rates(2,6,7). In cases of thin endometrium and 
recurrent pregnancy loss, injection of filgrastim (granulocyte 
colony-stimulating factor) into the uterine cavity is suggested 
as a means of increasing implantation and pregnancy rates(8,9).
It has been hypothesized that the local expression of GnRH and 
its receptor may play a role in endometrial conditioning during 
implantation because GnRH receptors are present in the follicles, 
embryo, placenta, tubal epithelium, and endometrium(10-14). 
Similarly, Casan et al.(12) hypothesized that GnRH receptors 
in the tubal epithelium may play a role in fertilization, early 
embryonic development, and implantation during the early 
luteal phase via a combination of paracrine and autocrine 
methods. Here, we compared the effects of GnRHa injected 
directly into the uterine cavity prior to ET on implantation rate, 
pregnancy, and live birth rates. This is the first study in the 
literature of GnRHa pre-installation before ET to investigate 
improvements in implantation and pregnancy rates in IVF.
Materials and Methods
In our study, we evaluated the effects of GnRHa injection prior to 
ET on implantation and pregnancy rates in our IVF programme 
executed between January 2012 and March 2013. Outcomes 
of IVF cycles during that period were collected retrospectively. 
Injection of GnRHa into the uterus before ET was a standard 
treatment protocol used by a single physician (BH) in our clinic 
during that period. Outcomes of IVF cycles treated with GnRHa 
were compared with those that received IVF treatment without 
GnRHa. Informed consent was obtained from all patients prior 
to the initiation of any procedure. This study was approved by 
the Institutional Review Board of Başkent University, Ankara, 
Turkey (approval number: KA 15/302).
Only fresh cycles in which ET was performed were included. 
In addition, only the cycles of patients who were aged ≤40 
years at the time of treatment, whose embryos were grade 1 
or 2, and whose endometrial thickness was ≥7 mm on the day 
of hCG were included. The exclusion criteria included cycles 
comprising difficult ET, cancellations for other reasons, and 
patients who had 3 or more previous unsuccessful IVF cycles. 
A total of 1965 consecutive IVF cycles were performed in our 
clinic between January 2012 and March 2013, among which 
142 cycles received GnRHa injection before ET. From this 
cohort of IVF cycles, 1155 met the necessary inclusion criteria, 
including 108 who received GnRHa injection before ET and 
1047 that did not. Primary outcomes in the two groups were 
implantation and live birth rates, and secondary outcomes were 
pregnancy and miscarriage rates. 
Ovarian hyperstimulation and oocyte pick up
Ovarian hyperstimulation was performed according to the long 
protocol, antagonist protocol, or clomiphene citrate-follicle 
stimulating hormone (CC-FSH) protocol. In the long protocol, 
downregulation was achieved using GnRH analogues initiated 
at the start of the proceeding luteal phase, with dosing halved 
beginning on the day of hyperstimulation and continued until 
the day of hCG treatment. The patients were then treated with 
recombinant FSH in the early follicular phase. In the antagonist 
protocol, FSH analogues were started at the beginning of the 
follicular phase of the cycle, and GnRH antagonists were added 
when the leading follicles reached 12-13 mm in diameter. In the 
CC-FSH protocol, patients were treated with 50 mg clomiphene 
citrate twice a day beginning on the third day of the cycle, and 
augmented with FSH on the third day of CC treatment. In all 
protocols, ovulation was induced using 250 µg recombinant 
hCG that was administered after the leading follicle reached a 
minimum of 17 mm in diameter. 
Oocyte retrieval was performed at 32-34 h after hCG 
administration. Oocytes were collected transvaginally. Metaphase 
II (MII) oocytes were prepared for the intracytoplasmic sperm 
injection (ICSI) procedure, which was performed after 2-2.5 h 
incubation. Embryos were transferred at the cleavage stage (3 
days after ICSI). 
Embryo grading
Embryos were graded according to the number and equivalence 
of cells and the percentage of vacuoles formed around them, the 
presence of multinucleation, and the status of the zona pellucida 
on the second and third days. According to the morphologic 
criteria above, embryos were graded as 1-4 on the cleavage 
stage embryo. According to Turkish legal regulations, patients 
aged younger than 35 years can only receive one embryo, and 
two embryos can be transferred in patients aged 35 years or 
older, as well as in patients who have already undergone two 
unsuccessful ICSI cycles. Thus, one or two embryos were 
transferred on the third day after fertilization.
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increase implantation and pregnancy rate in in vitro fertilization. 
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Gonadotropin releasing hormone agonist injection and 
embryo transfer
For patients receiving GnRHa treatment, the vaginal cavity was 
washed with warm saline and embryo medium, followed by 
treatment with 0.5 mL GnRHa (including 0.1 mg/mL triptoreline 
acetate, Ferring, Greece), which was delivered via an embryo 
catheter under abdominal ultrasonography guidance. GnRHa was 
injected into the uterine cavity when the tip of the catheter reached 
1 cm below the inner cavity of uterine fundus. Pre-selected 
embryos were then transferred into the uterine cavity after 10 min.
Luteal support
All patients received luteal support, including 90 mg/day 
progesterone administered intra-vaginally starting on the day of 
ET and continued for 12 days. 
Serum hCG levels were analyzed on day 12, with levels >10 mIU/
mL suggestive of pregnancy. Clinical pregnancy was accepted 
as positive if the fetal gestational sac was apparent and a fetal 
heartbeat was regularly detected. The implantation rate was 
calculated as the number of gestational sacs seen on transvaginal 
ultrasound per number of transferred embryos. Miscarriage rates 
were calculated as the number of miscarriages before 12 weeks 
of gestation per cycles of ET. The live birth rate was calculated as 
the number of live births per IVF cycles with ET. 
Statistical Analysis
Demographic data for each group are presented as the mean 
± standard deviations, or the median, with minimum and 
maximum or percentage values. The chi-square test was used 
to compare categorical data, and the Mann-Whitney U test was 
used to compare continuous variables that were non-normally 
distributed. Student’s t-test was used to compare continuous 
data with normal distribution. P values <0.05 were considered 
statistically significant. Data were analyzed using SPSS version 
18.0 for Windows (SPSS, Inc., USA).
Results
After the exclusion of 34 cycles from the study and 474 cycles 
from the control groups, 108 IVF cycles formed the study and 
1047 IVF cycles formed the control groups. Thirty-four cycles 
in the GnRHa group were excluded from the study.
Patient characteristics including age, duration of infertility, 
bilateral ovarian antral follicle counts on the day of early 
Table 1. Characteristics of study groups
GnRHa (+)
n=108
Control group
n=1047
p
Female age (y) 30.4±4 31.2±4 0.10
Infertility duration (y) 5.7±4 5.8±4 0.78
Antral follicle (n) 5.6±2 5.1±2 0.06
Estradiol level on hCG day (pg/mL) 1631±947 1561±1068 0.51
Progesterone level on hCG day (ng/mL)* 0.45 (0.1-1.9) 0.40 (0.0-2.2) 0.21
Endometrial thickness on hCG day (mm) 11.1±2.1 10.8±2.0 0.07
Ovarian hyperstimulation duration (d) 9.0±1 9.0±2 0.90
Total gonadotropin doses (IU) 1987±695 2009±760 0.79
Total oocytes after OPU (n) 12.2±5.6 10.9±6.2 0.12
MII oocyte (n) 9.9±5 8.4±5 0.09
Transferred embryo (n) 1.2±0.4 1.2±0.4 0.86
Grade 1 embryo (n)* 0.3 (0-2) 0.3 (0-2) 0.21
Grade 2 embryo (n) 0.8±0.6 0.9±0.6 0.17
IVF reasons (%)
                Male factor
                Unexplained
                Anovulation
                Poor ovarian reserve
                Endometriosis
                Tubal factor
34.5
22.1
26.3
8.3
5.2
2.8
35.1
25.6
24.3
9.8
5.3
3.0
0.87
p-values according to the χ2 test for categorical data
*Student’s t-test for normally distributed data or the Mann-Whitney U test for non-normally distributed quantitative data
Values were means ± standard deviation and medians for non-normally distributed quantitative data
GnRHa: Gonadotropin releasing hormone agonist, n: Number, y: Year, d: Day, IU: International units, hCG: Human chorionic gonadotropin, OPU: Oocyte pick-up, MII: Metaphase II, 
IVF: In vitro fertilization
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follicular phase, estradiol and progesterone levels, endometrial 
thickness on the day of hCG injection, duration of ovarian 
hyperstimulation, total dose of gonadotropins used for ovarian 
stimulation, number of total oocytes and MII oocytes obtained 
on the oocyte pick-up day, grade of the embryos, number of 
transferred embryos, and the reasons of IVF cycles were similar 
in both groups (Table 1).
Ovarian hyperstimulation was achieved using the long, agonist, 
or CC-FSH protocols. The long protocol was used in 23.1% and 
25% of cycles for the GnRHa and controls groups, respectively. 
The agonist protocol was used for 74.1% and 70.6% of cycles, 
and the CC-FSH protocol was used in 4.4% and 2.8% of cycles 
in the GnRHa and control groups, respectively (p=0.63).
Pregnancy, live birth, miscarriage, and implantation rates were 
44.4%, 27.8%, 15.7%, and 31%, respectively, in the GnRHa group 
compared with 41.7%, 26.1%, 15.7%, and 30%, respectively, in 
the control group. No statistically significant differences were 
observed between the two groups in terms of IVF results (Table 
2). Similarly, the transfer of one or two embryos did not affect 
pregnancy, live birth, or implantation rates in the GnRHa group 
relative to the controls (p>0.05) (Table 3). 
Discussion
In this study, we compared pregnancy-related IVF outcomes 
in patients treated with GnRHa immediately before ET with 
those receiving similar treatment without GnRHa stimulation. 
We observed no statistically significant differences in terms 
of implantation, pregnancy, live birth, or miscarriage rates 
between the groups.
During IVF treatment, spontaneous pregnancy is encountered 
in 1% of cycles using the long protocol when GnRHa is started 
during the previous luteal phase, consistent with an observation 
that inadvertent GnRHa injection might improve pregnancy 
rates(15). Luteal phase injection of GnRHa has been suggested 
as a method to increase pregnancy and live birth rates by 
enhancing luteinizing hormone secretion and supporting 
maintenance of the corpus luteum(5,16,17). Alternatively, GnRHa 
is also thought to affect GnRH receptors in the endometrium 
and embryo, thereby increasing implantation and pregnancy 
rates in donor cycles(5). Based upon these observations, GnRHa 
injection directly into the uterine cavity has been suggested as a 
possible method for enhancing implantation rate, although no 
direct analyses have been performed.
Previous studies have offered strong support for the use of 
intrauterine therapy as a means of improving IVF outcomes. 
In a series of prospective, randomized controlled studies, hCG 
injection into the uterine cavity before ET increased pregnancy 
and live birth rates(2,6,7). Under normal conditions, trophoblastic 
GnRH has been implicated as one of the primary regulators of 
the synthesis and secretion of hCG in peri-implantation embryos 
in murine models. Similarly, human placental GnRH plays 
an important role in the synthesis and secretion of hCG(11,18). 
Table 2. In vitro fertilization outcomes of the two groups
GnRHa (+) n=108 Control group (-) n=1047 p
Pregnancy rate/cycle n (%) 48/108 (44.4) 437/1047 (41.7) 0.32
Live birth rate/cycle n (%) 30/108 (27.8) 273/1047 (26.1) 0.38
Miscarriage rate/cycle n (%) 17/108 (15.7) 164/1047 (15.7) 0.36
Implantation rate/cycle (%) 31.2±44 30.7±43 0.86
p-values according to the χ2 test for categorical data
Student’s t-test for normally distributed data
GnRHa: Gonadotropin releasing hormone agonist, n: Number 
Table 3. Outcomes of in vitro fertilization according to the number of transferred embryos
GnRHa (+) Control group p
One embryo transfer 
                 Pregnancy rate n (%)
                 Live birth rate n (%)
                 Miscarriage rate n (%)
                 Implantation rate (%)
34/79 (43.0)
20/79 (25.3)
14/79 (17.8)
32±4.7
304/750 (40.5)
191/750 (25.5)
113/750 (15.2)
34±4.7
0.37
0.55
0.13
0.83
Two embryo transfer 
                 Pregnancy rate n (%)
                 Live birth rate n (%)
                 Miscarriage rate n (%)
                 Implantation rate (%)
14/29 (48.3)
10/29 (34.5)
4/29 (13.8)
27±34
133/293 (45.4)
82/293 (28.0)
51/293 (17.4)
22±31
0.45
0.29
0.83
0.38
p-values according to the χ2 test for categorical data
Student’s t-test for normally distributed data
GnRHa: Gonadotropin releasing hormone agonist, n: Number
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Alternatively, GnRHa may also increase pregnancy rates by 
increasing the synthesis of hCG in the endometrium. However, 
despite these observations, the precise mechanism by which 
GnRHa improves pregnancy rates has remained unknown. 
Finally, in vitro studies investigating the effects of GnRHa during 
cleavage and implantation will be necessary to fully understand 
the mechanisms on GnRHa activity.
Study Limitations
The most important limitation of our study is that only a single 
physician used GnRHa injections, so we cannot rule out the 
selection or performance bias in the follow-up of IVF treatment. 
The retrospective nature of this analysis represents the second 
significant limitation of this work; however, we tried to 
minimize both limitations by strictly controlling the inclusion 
and exclusion criteria. Patients with thin endometriums were 
excluded from the study; although there are studies suggesting 
the opposite(19), most authors emphasize that pregnancy rates 
were lower in patients with thin endometriums(20-22). Similarly, 
the exclusion of patients aged >40 years was preferred to limit 
the effects of embryo quality on implantation. Only first or 
second IVF cycles of the same patient were included in this 
analysis to minimize the effects of recurrent implantation failure 
and to exclude the recurrent number of IVF cycles of the same 
patient. Finally, only cycles in which grade 1 or 2 embryos were 
transferred were included as a means of controlling for the 
effects of embryo quality. 
Conclusion
No statistically significant differences in terms of implantation, 
pregnancy, live birth, and miscarriage rates were observed 
in patients treated with GnRHa prior to ET relative to the 
controls. According to this study, GnRHa injection into the 
uterine cavity prior to ET is not recommended as a means of 
increasing implantation or pregnancy rates in IVF. However, in 
order to be able to see the net effect of GnRHa injection into the 
uterine cavity before ET in IVF, further prospective randomized 
controlled studies are needed.
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